Corteva Reports Third-Quarter 2026 Results; Updates FY 2026 Outlook

Corteva’s Q3 loss and weak Latin America offset North America gains; guidance cut for 2026.

What the company is saying

Corteva, Inc. (NYSE:CTVA) frames its third-quarter and year-to-date 2026 results as a demonstration of operational discipline and new product strength, despite adverse market conditions. The company highlights strong organic sales and volume growth in North America (7% and 19%, respectively) and EMEA (14%), while openly acknowledging significant pricing and volume pressure in Latin America, especially Brazil. Management attributes the Latin America weakness to competitive pressure on mature molecules, elevated channel inventory, and farmer liquidity constraints. CEO Luke Kissam emphasizes that innovation, productivity, and disciplined execution remain the foundation for long-term growth, even as full-year guidance is revised downward to reflect the deteriorating Brazilian market. The announcement also notes the Board’s authorization of the first common dividend post-spin, but omits the dividend amount or timing. The tone is factual, with explicit discussion of both positive and negative drivers.

What the data suggests

Third quarter 2026 net sales fell 9% year-over-year to $1.59 billion, with a net loss from continuing operations of $(54) million and GAAP EPS of $(0.08). Organic sales also declined 9%, with operating EBITDA down 17% to $222 million and adjusted pro forma operating EPS at $0.06. Year-to-date, net sales were $5.36 billion (down 1%), with income from continuing operations of $112 million and GAAP EPS of $0.16. Adjusted pro forma operating EBITDA was $943 million (flat year-over-year), and adjusted pro forma operating EPS was $0.76. The EBITDA margin improved 30 basis points to 17.6% year-to-date, but third-quarter margin eroded by 140 basis points. Regional data show North America’s organic sales up 7% and volume up 19%, while Latin America’s organic sales plunged 31% and volume dropped 24%, driven by Brazil’s market challenges. The company cut full-year 2026 guidance, now expecting adjusted pro forma operating EBITDA of $1.1–$1.125 billion and EPS of $0.76–$0.80. Management’s stated causes for the downturn are competitive and pricing pressures in Brazil and the U.S., with North America and EMEA showing resilience. The figures indicate a company under pressure, with gains in some regions unable to offset sharp declines in others.

Analysis

The announcement is a standard quarterly and year-to-date financial disclosure, with the majority of claims supported by realised, audited figures for sales, EBITDA, and EPS. The only forward-looking elements are the updated full-year 2026 guidance for adjusted pro forma operating EBITDA and EPS, which are typical in earnings releases and not presented with exaggerated language. The tone is factual, and there is no evidence of narrative inflation or overstatement; the company openly discusses both positive (North America growth, margin expansion) and negative (Latin America decline, pricing pressure) developments. No large capital outlay or long-dated, uncertain returns are discussed, and the dividend authorization is mentioned without promotional framing or quantitative detail. The gap between narrative and evidence is minimal, as the release is balanced and transparent about both strengths and challenges.

Risk flags

• ●Latin America, especially Brazil, faces severe market headwinds, including a 31% organic sales decline and 24% volume drop in Q3, driven by competitive pricing, high channel inventory, and farmer liquidity constraints. This exposes Corteva to continued revenue and margin pressure in a key growth region.
• ●The company’s Q3 net loss of $(54) million and 17% drop in operating EBITDA highlight vulnerability to pricing and volume shocks, especially as mature product cycles and competitive dynamics intensify. Sustained losses or further margin erosion could impact future investment and dividend capacity.
• ●The updated 2026 guidance reflects a more pessimistic outlook, with EBITDA and EPS targets lowered due to Brazil’s deterioration. If market conditions worsen further or spread to other regions, additional guidance cuts may be necessary, increasing uncertainty for investors.
• ●The Board’s authorization of a post-spin dividend is announced without specifying amount or timing, leaving investors unclear on the scale or sustainability of future shareholder returns. Lack of detail here limits the ability to assess the dividend’s significance or reliability.

Bottom line

Corteva’s Q3 and year-to-date results show a company grappling with regional divergence: North America and EMEA are growing, but Latin America, particularly Brazil, is dragging down consolidated performance. The company has revised its full-year 2026 guidance downward, now targeting $1.1–$1.125 billion in adjusted pro forma operating EBITDA and $0.76–$0.80 in EPS, reflecting a challenging market that is unlikely to improve materially before year-end. The Q3 net loss and EBITDA decline underscore the impact of pricing and volume pressures in key markets, while the lack of detail on the newly authorized dividend leaves open questions about future capital returns. Investors should focus on whether the company can stabilize Latin America and deliver on its revised guidance in the upcoming Q4 results. The most important takeaway is that while Corteva’s innovation and operational strengths are evident in some regions, macro and competitive pressures—especially in Brazil—are dictating near-term financial outcomes.

Announcement summary

(NYSE:CTVA) Corteva, Inc. reported financial results for the third quarter and nine months ended September 30, 2026. For the third quarter of 2026, net sales were $1.59 billion, representing a 9% decrease compared to the same period in 2025. The company reported a loss from continuing operations after tax of $(54) million and a GAAP EPS of $(0.08) for the quarter. Organic sales for the quarter were $1.58 billion, with operating EBITDA of $0.22 billion and adjusted pro forma operating EPS of $0.06. Year-to-date 2026 net sales were $5.36 billion, up 1% from the prior year, with income from continuing operations after tax of $112 million and GAAP EPS of $0.16. Organic sales for the year-to-date period were $5.20 billion, operating EBITDA was $0.94 billion, and adjusted pro forma operating EPS was $0.76. The adjusted pro forma operating EBITDA margin expanded by 30 basis points to 17.6%. The Board of Directors authorized the first common dividend post spin. The company updated its full-year 2026 guidance, now expecting adjusted pro forma operating EBITDA to be in the range of $1.1 billion to $1.125 billion and adjusted pro forma operating EPS between $0.76 and $0.80 per share. In the third quarter, North America reported 7% organic sales growth with volume up 19%, EMEA reported 14% organic sales growth, Latin America organic sales declined 31% with volumes down 24%, and Asia Pacific reported 5% organic sales growth with 7% volume growth. Third quarter operating EBITDA was $222 million, down 17% from the prior year, and the margin declined by 140 basis points. Year-to-date operating EBITDA was $943 million, flat compared to the prior year. Net sales by region for the third quarter were: North America $574 million, EMEA $239 million, Latin America $570 million, and Asia Pacific $208 million. Year-to-date net sales by region were: North America $1,826 million, EMEA $1,438 million, Latin America $1,403 million, and Asia Pacific $690 million. The company cited pricing pressure in North America and Latin America, particularly due to acetochlor in the U.S. and competitive dynamics on molecules late in their lifecycle in Brazil. The company will host a live webcast of its third quarter 2026 earnings conference call on November 12, 2026, at 10:30 a.m. ET.

Disagree with this article?